FDA gives Indian drugmaker Glenmark its first approval for generics produced at U.S. plant

Glenmark
The FDA gave Indian generic drugmaker Glenmark its first supplemental Abbreviated New Drug Application approval for its U.S. facility. (Glenmark)

The FDA gave Indian generic drugmaker Glenmark its first supplemental Abbreviated New Drug Application approval for its manufacturing facility in Monroe, North Carolina, the company said.

The regulatory agency’s approval is for the production of atovaquone and proguanil hydrochloride tablets, a generic version of GlaxoSmithKline's Malarone used to treat malaria.

"This approval is an important milestone for our U.S. business, as the Monroe, North Carolina, site will expand our portfolio by providing the manufacturing foundation for future product approvals," Robert Matsuk, Glenmark’s president for North America & Global API, said in a statement. "Additionally, we are pleased that the investment we've made in our site will continue to create new, high-quality jobs in the Monroe community, where we have a commitment to long-term growth and expansion."

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

RELATED: Glenmark to build $100M plant in North America

Glenmark invested more than $100 million in the Monroe site, and has plans to expand the plant in the coming years. It is the company’s first plant in the U.S. and was designed to produce a variety of fixed dose pharmaceutical formulations. When operating at peak capacity, the plant is expected to produce 300-400 million tablets and capsules, 20-25 million vials and prefilled syringes and 25-30 million ampoules for inhaled formulations.

The company now has 16 manufacturing sites located in Europe, India and the U.S.

Read more on

Suggested Articles

Generic pain drug maker Lannett is closing its plant in Wyoming and laying off the remaining 80 employees.

Turkey is getting its first locally produced mAb via an Iranian biosimilars marker and the $100 million plant it built there.

Teva is recalling 10 more lots of losartan as blood pressure drugs tainted with suspected carcinogens continue to pop up in the U.S. supply chain.